P

Inventor

GOVINDAN SERENGULAM V

US108 patents
⚠️ This page may combine multiple inventors who share the name “GOVINDAN SERENGULAM V”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.

IMMUNOMEDICS INC

40 patents
US7999083B2Aug 16, 2011

Immunoconjugates with an intracellularly-cleavable linkage

IMMUNOMEDICS INC184 citations99
US7591994B2Sep 22, 2009

Camptothecin-binding moiety conjugates

IMMUNOMEDICS INC129 citations99
US7585491B2Sep 8, 2009

Immunoconjugates with an intracellularly-cleavable linkage

IMMUNOMEDICS INC148 citations99
US9492566B2Nov 15, 2016

Antibody-drug conjugates and uses thereof

IMMUNOMEDICS INC61 citations98
US9138485B2Sep 22, 2015

Immunoconjugates with an intracellularly-cleavable linkage

IMMUNOMEDICS INC32 citations98
US9028833B2May 12, 2015

Dosages of immunoconjugates of antibodies and SN-38 for improved efficacy and decreased toxicity

IMMUNOMEDICS INC48 citations98
US8759496B2Jun 24, 2014

Immunoconjugates with an intracellularly-cleavable linkage

IMMUNOMEDICS INC38 citations98
US9198978B2Dec 1, 2015

Immunoconjugates with an intracellularly-cleavable linkage

IMMUNOMEDICS INC20 citations96
US9102735B2Aug 11, 2015

Immunoconjugates with an intracellularly-cleavable linkage

IMMUNOMEDICS INC27 citations96
US8999344B2Apr 7, 2015

Immunoconjugates with an intracellularly-cleavable linkage

IMMUNOMEDICS INC19 citations96
US6558669B1May 6, 2003

Stable radioiodine conjugates and methods for their synthesis

IMMUNOMEDICS INC35 citations96
US6120768ASep 19, 2000

Dota-biotin derivatives

IMMUNOMEDICS INC68 citations96
US10682347B2Jun 16, 2020

Dosages of immunoconjugates of antibodies and SN-38 for improved efficacy and decreased toxicity

IMMUNOMEDICS INC11 citations94
US10137196B2Nov 27, 2018

Dosages of immunoconjugates of antibodies and SN-38 for improved efficacy and decreased toxicity

IMMUNOMEDICS INC18 citations94
US10130626B2Nov 20, 2018

Dosages of immunoconjugates of antibodies and SN-38 for improved efficacy and decreased toxicity

IMMUNOMEDICS INC18 citations94
US10265414B2Apr 23, 2019

Immunoconjugates with an intracellularly-cleavable linkage

IMMUNOMEDICS INC6 citations93
US10130718B2Nov 20, 2018

Antibody-drug conjugates and uses thereof

IMMUNOMEDICS INC12 citations93
US10064957B2Sep 4, 2018

Immunoconjugates with an intracellularly-cleavable linkage

IMMUNOMEDICS INC14 citations93
US9675706B2Jun 13, 2017

Immunoconjugates with an intracellularly-cleavable linkage

IMMUNOMEDICS INC6 citations93
US9629926B2Apr 25, 2017

Antibody-SN-38 immunoconjugates with a CL2A linker

IMMUNOMEDICS INC21 citations93
US9522959B2Dec 20, 2016

Dosages of immunoconjugates of antibodies and SN-38 for improved efficacy and decreased toxicity

IMMUNOMEDICS INC13 citations93
US9493573B2Nov 15, 2016

Dosages of immunoconjugates of antibodies and SN-38 for improved efficacy and decreased toxicity

IMMUNOMEDICS INC12 citations93
US9493574B2Nov 15, 2016

Dosages of immunoconjugates of antibodies and SN-38 for improved efficacy and decreased toxicity

IMMUNOMEDICS INC7 citations93
US9480756B2Nov 1, 2016

Immunoconjugates with an intracellularly-cleavable linkage

IMMUNOMEDICS INC13 citations93
US9388237B2Jul 12, 2016

Immunoconjugates with an intracellularly-cleavable linkage

IMMUNOMEDICS INC12 citations93
US9345783B2May 24, 2016

Immunoconjugates with an intracellularly-cleavable linkage

IMMUNOMEDICS INC12 citations93
US9238084B2Jan 19, 2016

Anti-mucin antibodies for early detection and treatment of pancreatic cancer

IMMUNOMEDICS INC36 citations93
US9233172B2Jan 12, 2016

Immunoconjugates with an intracellularly-cleavable linkage

IMMUNOMEDICS INC12 citations93
US9226973B2Jan 5, 2016

Dosages of immunoconjugates of antibodies and SN-38 for improved efficacy and decreased toxicity

IMMUNOMEDICS INC7 citations93
US8834886B2Sep 16, 2014

Camptothecin-binding moiety conjugates

IMMUNOMEDICS INC18 citations93
US8758752B2Jun 24, 2014

RS7 antibodies

IMMUNOMEDICS INC16 citations93
US7147856B2Dec 12, 2006

Stable radioiodine conjugates and methods of their synthesis

IMMUNOMEDICS INC13 citations93
US5846741ADec 8, 1998

Boron neutron capture therapy using pre-targeting methods

IMMUNOMEDICS INC31 citations93
US9694088B2Jul 4, 2017

Pro-drug form (P2PDox) of the highly potent 2-pyrrolinodoxorubicin conjugated to antibodies for targeted therapy of cancer

IMMUNOMEDICS INC11 citations92
US9375489B2Jun 28, 2016

Antibody-SN-38 immunoconjugates with a CL2A linker

IMMUNOMEDICS INC21 citations92
US9107960B2Aug 18, 2015

Antibody-SN-38 immunoconjugates with a CL2A linker

IMMUNOMEDICS INC16 citations92
US8877202B2Nov 4, 2014

Pro-drug form (P2PDOX) of the highly potent 2-pyrrolinodoxorubicin conjugated to antibodies for targeted therapy of cancer

IMMUNOMEDICS INC27 citations92
US5965131AOct 12, 1999

Delivery of diagnostic and therapeutic agents to a target site

IMMUNOMEDICS INC30 citations92
US5958408ASep 28, 1999

Delivery of diagnostic and therapeutic agents to a target site

IMMUNOMEDICS INC44 citations92
US7230085B2Jun 12, 2007

Anti-DOTA antibody

IMMUNOMEDICS INC25 citations90

GOVINDAN SERENGULAM V

10 patents

Showing the top 50 of 108 patents by PatentIndex Score.